Condition: Triple Negative Breast Neoplasms · Triple Negative Breast Cancer · Breast Neoplasms · Sponsor: Okayama University
This is a Phase II, single-arm, open label study to evaluate Olaparib plus Pembrolizumab following platinum-based chemotherapy plus Pembrolizumab as neoadjuvant therapy for germline BRCA (gBRCA) 1/2 mutated triple negative breast cancer (TNBC). Pembrolizumab in combination with weekly paclitaxel and carboplatin (treatment 1) is followed by Pembrolizumab in combination with Olaparib (treatment 2) in neoadjuvant setting and Pembrolizumab in combination with Olaparib in adjuvant setting will be studied
This description comes directly from the study's public registry record.
Yuko Takahashi, MD., PhD. · +81-86-223-7151 · yukotaka@okayama-u.ac.jp
Hironobu TAN, PhD. · +81-86-235-7994 · hironobu_tan@okayama-u.ac.jp
Always discuss trial participation with your own doctor first.
| Gifu University Hospital | Gifu, Gifu, Japan | Recruiting |
| Okayama University Hospital | Okayama, Japan | Recruiting |
| St. Luke's International Hospital | Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05485766